FDA grants orphan drug designation to OTX-2002 for hepatocellular carcinoma

The FDA granted orphan drug designation to OTX-2002 for the treatment of hepatocellular carcinoma, according to the agent’s manufacturer.OTX-2002 (Omega Therapeutics) is a messenger RNA therapeutic delivered through lipid nanoparticles. It is designed to downregulate c-MYC pre-transcriptionally via epigenetic modulation and potentially overcome MYC autoregulation, according to a Omega Therapeutics-issued press release. The MYC oncogene has been linked to aggressive disease in as many as 70% of patients with HCC, according to the release.”HCC is a devastating illness that often developsRead More

Generated by Feedzy